Skip to main content
    Z

    Zentalis Pharmaceuticals Llc (ZNTL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.60
    -0.10 (-5.88%)

    Market Cap: $167.05M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Zentalis Pharmaceuticals Llc (ZNTL) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Zentalis Pharmaceuticals Llc are LENZ Therapeutics (LENZ), Cellectis SA (CLLS) and Greenwich Lifesciences (GLSI). By market cap, Zentalis Pharmaceuticals Llc ranks 7th of the 13 companies on this page; Prelude Therapeutics (PRLD) is the largest at $275.32M.

    Peer Comparison

    ZNTL's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Zentalis Pharmaceuticals Llc (ZNTL)$167.05MN/AN/A0.0%N/A0.0%0.00%
    LENZ Therapeutics Inc (LENZ)$129.77MN/A9.7x0.0%N/A-72.9%0.00%
    Cellectis SA (CLLS)$118.86MN/A1.8x0.0%-74.1%-85.4%0.00%
    Greenwich Lifesciences Inc (GLSI)$219.29MN/AN/A0.0%N/A0.0%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Cartesian Therapeutics Inc. (RNAC)$193.69MN/A179.8x0.0%147.2%-92.9%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    Sol Gel Technologies Ltd (SLGL)$180.46MN/A125.4x0.0%N/A-96.6%0.00%
    Lineage Cell Therapeutics Inc (LCTX)$231.35MN/A18.7x16.2%-6.7%-61.0%0.00%
    Invivyd Inc. (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    Minerva Neurosciences Inc (NERV)$114.62MN/AN/A0.0%N/A0.0%0.00%
    PDS Biotechnology Corp (PDSB)$107.07MN/AN/A0.0%-149.8%0.0%0.00%
    Zura Bio Limited Class A Ordinary Shares (ZURA)$119.44MN/AN/A0.0%N/A0.0%0.00%
    Peer median$163.68MN/A16.3x0.0%-40.4%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Zentalis Pharmaceuticals Llc, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    LENZ Therapeutics Inc (LENZ)
    LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders...
    LENZ competitors
    Cellectis SA (CLLS)
    Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors...
    CLLS competitors
    Greenwich Lifesciences Inc (GLSI)
    Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 /...
    GLSI competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors
    Cartesian Therapeutics Inc. (RNAC)
    Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs...
    RNAC competitors
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    Sol Gel Technologies Ltd (SLGL)
    Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological...
    SLGL competitors
    Lineage Cell Therapeutics Inc (LCTX)
    Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment...
    LCTX competitors
    Invivyd Inc. (IVVD)
    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery...
    IVVD competitors
    Minerva Neurosciences Inc (NERV)
    Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products...
    NERV competitors
    PDS Biotechnology Corp (PDSB)
    PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies.
    PDSB competitors
    Zura Bio Limited Class A Ordinary Shares (ZURA)
    Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases.
    ZURA competitors

    Frequently Asked Questions About ZNTL

    Who are Zentalis Pharmaceuticals Llc's main competitors?

    The companies most similar to Zentalis Pharmaceuticals Llc include LENZ Therapeutics (LENZ), Cellectis SA (CLLS), Greenwich Lifesciences (GLSI), Prelude Therapeutics (PRLD) and Cartesian Therapeutics (RNAC), listed from the closest match.

    Who is Zentalis Pharmaceuticals Llc's biggest competitor?

    Prelude Therapeutics (PRLD) is the largest of the similar companies at $275.32M; LENZ Therapeutics (LENZ) is the closest match by business profile, size, sector and industry.

    How does ZNTL stock compare with its competitors?

    ZNTL's net margin is 0.0% against a peer median of 0.0%.

    Which of Zentalis Pharmaceuticals Llc's competitors pays a higher dividend?

    Zentalis Pharmaceuticals Llc pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Zentalis Pharmaceuticals Llc bigger than its competitors?

    No. Zentalis Pharmaceuticals Llc is 7th by market cap among the 13 companies on this page; the largest is Prelude Therapeutics (PRLD) at $275.32M.